Insmed's (INSM) brensocatib offering, "likely to be among the strongest launches in 2025," will be driven by high patient and physician demand for the chronic lung disease treatment, RBC Capital Markets said Monday in a report.
The drug, which will likely be approved with a clean label by Aug. 12, may reach a peak sales opportunity of $8.2 billion for bronchiectasis treatment with $53 million in 2025 sales, the investment firm said.
The drug has potential beyond bronchiectasis with mid-2025 data on chronic rhinosinusitis without nasal polyps possibly offering a $1 billion market opportunity, while 2026 data from trials of hidradenitis suppurativa, a chronic skin conditions, may expand brensocatib into specialty dermatology, adding $300 million in sales, RBC said.
Mycobacterium avium complex lung disease treatment Arikayce is expected to generate $425 million in 2025 sales and may expand if a phase 3 trial is successful, driving revenue to $1 billion, RBC said.
RBC initiated coverage on Insmed with an outperform rating and a $100 price target.
Shares of the company fell 3% in recent Tuesday trading.
Price: 77.63, Change: -2.40, Percent Change: -3.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。